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Abstract
Background: Salmonella enterica serotype Typhi can colonize and persist in the biliary tract of infected individuals, resulting
in a state of asymptomatic chronic carriage. Chronic carriers may act as persistent reservoirs of infection within a community
and may introduce infection to susceptible individuals and new communities. Little is known about the interaction between
the host and pathogen in the biliary tract of chronic carriers, and there is currently no reliable diagnostic assay to identify
asymptomatic S. Typhi carriage.
Methodology/Principal Findings: To study host-pathogen interactions in the biliary tract during S. Typhi carriage, we
applied an immunoscreening technique called in vivo-induced antigen technology (IVIAT), to identify potential biomarkers
unique to carriers. IVIAT identifies humorally immunogenic bacterial antigens expressed uniquely in the in vivo
environment, and we hypothesized that S. Typhi surviving in the biliary tract of humans may express a distinct antigenic
profile. Thirteen S. Typhi antigens that were immunoreactive in carriers, but not in healthy individuals from a typhoid
endemic area, were identified. The identified antigens included a number of putative membrane proteins, lipoproteins, and
hemolysin-related proteins. YncE (STY1479), an uncharacterized protein with an ATP-binding motif, gave prominent
responses in our screen. The response to YncE in patients whose biliary tract contained S. Typhi was compared to responses
in patients whose biliary tract did not contain S. Typhi, patients with acute typhoid fever, and healthy controls residing in a
typhoid endemic area. Seven of 10 (70%) chronic carriers, 0 of 8 bile culture-negative controls (0%), 0 of 8 healthy
Bangladeshis (0%), and 1 of 8 (12.5%) Bangladeshis with acute typhoid fever had detectable anti-YncE IgG in blood. IgA
responses were also present.
Conclusions/Significance: Further evaluation of YncE and other antigens identified by IVIAT could lead to the development
of improved diagnostic assays to identify asymptomatic S. Typhi carriers.
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Introduction
Salmonella enterica serovars Typhi (S. Typhi) and Paratyphi A (S.
Paratyphi A) are human-specific pathogens, and the predominant
cause of enteric (typhoid) fever globally. Enteric fever affects over
21 million people each year, resulting in 200,000 deaths [1].
Infection with S. Typhi and S. Paratyphi A usually begins with
ingestion of contaminated water or food. The pathogens invade
the gastrointestinal mucosa, translocate to the lymphoid follicles
where they survive and replicate within macrophages, and then
disseminate via the bloodstream to the liver, spleen, intestinal
lymph nodes, bone marrow, and gallbladder [2]. With adequate
treatment, most patients recover from their acute stage of illness
and clear infection. However, a small percentage of S. Typhi (and
S. Paratyphi A) infected individuals develop a chronic, but
apparently asymptomatic, infection in the biliary tract that can
persist for decades [3–6]. The likelihood of this is not known, but it
is estimated that chronic carriage can complicate perhaps 1–3% of
acute infections [7].
Since S. Typhi and S. Paratyphi A are human-restricted
pathogens, chronic carriers may act as reservoirs of infection
within a community. They contribute to the transmission cycle
through the intermittent shedding of bacteria in feces (especially in
areas of low transmission [8]) and may act as vehicles for
introducing S. Typhi and S. Paratyphi A into previously uninfected
communities. Therefore, correctly identifying and treating asymp-
tomatic chronic carriers is critical for the long-term control of
enteric fever. Currently, there is no reliable diagnostic assay to
identify asymptomatic S. Typhi and S. Paratyphi A carriage.
Bacterial stool culture has been used, yet is challenging due to the
expense and logistics of obtaining multiple samples from patients,
since shedding is typically low level and intermittent [5].
Measurement of antibody responses to the S. Typhi capsular Vi
antigen has been previously described as a potential method to
detect chronic S. Typhi carriers [7]. In laboratory settings, IgG to
the Vi antigen has been shown to have a sensitivity of 75% and
specificity of .95% and has proven to complement other
strategies in outbreak investigations [7,9–11]. However, its role
in detecting asymptomatic carriers in a general endemic-zone
population is unclear. In Chile, anti-Vi antibody responses had a
sensitivity of 75% and specificity of 92%–97% for S. Typhi
carriage; however, due to a low prevalence rate of carriage in the
general population, its positive predictive value was only 8–17%
[12]. In Vietnam, a large community-based survey for anti-Vi
antibodies demonstrated a 3% positivity rate in the population;
however, S. Typhi was never detected in the stool of individuals
identified by such anti-Vi screening [13].
Understanding the mechanisms involved in development and
persistence of the carrier state may facilitate development of
improved diagnostic assays and therapeutic approaches for S.
Typhi carriage. Currently, little is known about host-pathogen
interactions in the biliary tract of chronic human carriers. Much of
what is known about biliary carriage has been extrapolated from in
vitro and murine studies with S. Typhimurium, which causes an
enteric fever-like illness in mice [5]. From these animal studies and
a complimentary study in humans, we know that gallstones
facilitate S. Typhi carriage [5]. In the presence of bile, the
bacterium regulates the expression of genes that allow it to
colonize and persist in the gallbladder through formation of
biofilms that mediate resistance against host defenses [14,15].
There are likely other niches of persistent infection outside of the
gallbladder, including the biliary tree, liver, and mesenteric lymph
nodes. This is suggested by the observation that although
cholecystectomy increases cure rates, it does not always result in
clearance of the pathogen in humans [16]. In a murine model of
Salmonella chronic infection, S. Typhimurium infection in Slc11a1
(Nramp1) wild-type mice demonstrated that the most common site
of persistent infection was in hemophagocytic macrophages within
mesenteric lymph nodes [2,17,18].
To advance our understanding of Salmonella pathogenesis of the
chronic carrier state, and identify potential biomarkers unique to
S. Typhi chronic carriers, we applied an immunoscreening
technique called in vivo-induced antigen technology (IVIAT) [19–
21]. IVIAT identifies humorally immunogenic bacterial antigens
expressed in vivo and not in bacteria grown in standard laboratory
conditions. We hypothesized that S. Typhi surviving in the biliary
tract of humans may express a proteomic profile distinct from that
expressed in bacteria grown using standard in vitro conditions or
during acute infection.
Methods
Ethics statement
This study was approved by the human studies committees of
the involved research institutions: Massachusetts General Hospital,
International Centre of Diarrheal Disease Research, Bangladesh
(icddr,b), Patan Hospital, The Nepal Health Research Council,
and the Oxford Tropical Research Ethics Committee. The study
was conducted according to the principles expressed in the
Declaration of Helsinki/Belmont Report, and informed written
consent was obtained from adult participants and from guardians
of children prior to study participation.
Bacterial strains, plasmids, and media
Salmonella enterica serotype Typhi strain CT18 [22] was obtained
from the Salmonella Genetic Stock Centre (Calgary, Alberta,
Canada). Genomic DNA from this strain was used to construct a
genomic inducible expression library in host strain Escherichia coli
strain BL21(DE3). Bacterial strains were grown in Luria-Bertani
(LB) media (with 50 mg/ml kanamycin for clones containing
pET30 constructs) and maintained at 280uC in LB broth
containing 15% glycerol.
Patient and control sera
Individuals undergoing elective cholecystectomy in Kath-
mandu, Nepal were enrolled. At the time of cholecystectomy, a
venous blood sample was stored and a bile sample was taken for
Author Summary
Salmonella enterica serotype Typhi is the cause of typhoid
fever and infects over 21 million individuals and causes
200,000 deaths each year. With adequate treatment, most
patients recover from their acute stage of illness and clear
infection. However, a small percentage of S. Typhi infected
individuals develop a chronic but asymptomatic infection
in the biliary tract that can persist for decades. Since S.
Typhi is a human-restricted pathogen, chronic carriers may
act as reservoirs of infection. Correctly identifying and
treating asymptomatic chronic carriers could be critical for
ultimate control of typhoid fever. Using an immunoscreen-
ing technique called in vivo-induced antigen technology
(IVIAT), we have identified potential biomarkers unique to
S. Typhi chronic carriers. Further evaluation of these
antigens could lead to the development of improved
diagnostic assays to detect asymptomatic S. Typhi carriers
in typhoid endemic zones, and to an improved under-
standing of the pathogenesis of S. Typhi in the chronic
carrier state.
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microbiologic analysis as previously described [6]. Patients were
categorized as (1) S. Typhi carriers if their bile culture was positive
for S. Typhi; (2) S. Paratyphi A carriers if their bile culture was
positive for S. Paratyphi A, or (3) cholecystectomy controls if their
bile cultures were negative for any organism. Sera samples were
also obtained from the following groups: (1) healthy Bangladeshi
residents of Dhaka (a typhoid endemic area) enrolled at the
International Centre for Diarrhoeal Disease Research, Bangladesh
(icddr,b); and (2) acute (day 0–3) and convalescent sera (day 14–28)
of Bangladeshi patients who presented to icddr,b with S. Typhi
bacteremia [23–25].
Construction of genomic inducible expression library
Genomic DNA was purified from S. Typhi strain CT18 using a
Genomic DNA Isolation kit (Qiagen, Valencia, Ca), sheared using
a Covaris sonicatior (Woburn, Ma) optimized to generate 0.5–
1.5 kb DNA fragments, and resulting fragments were gel purified
using the Qiagen Qiaquick Gel Extraction kit. After terminal
overhangs were removed using End-It DNA end-repair kit
(Epicenter Biotechnologies, Madison, WI), the blunt-end products
were ligated into pET-30c vectors (Novagen, San Diego, CA) that
had been digested with EcoRV and treated with calf intestinal
alkaline phosphatase. The library was electroporated into E. coli
DH5a and bacteria were plated onto selective LB media
containing kanamycin. After overnight incubation at 37uC, the
plates were scraped and the plasmid DNA from collected colonies
was recovered using Qiagen Miniprep kit. EcoRI and KpnI
digestion was performed on a random sample of plasmids, and
an insertion frequency greater than 80% and insert size between
500 to 1500 bp was verified. The plasmid DNA mixture was
electroporated into E. coli BL21 (DE3), and collected colonies were
stored in LB broth containing 15% glycerol.
Screening for antigens uniquely expressed in vivo in S.
Typhi carriers
Convalescent sera of 5 patients with bile cultures positive for S.
Typhi were pooled, and adsorbed with in vitro grown S. Typhi
strain CT18 and E. coli BL21 (DE3) [19]. Immunoblot techniques
were used as previously described [19]. Briefly, the genomic
library was plated on LB plates containing kanamycin to obtain a
colony density of approximately 500 to 1000 clones per plate.
After overnight incubation at 37uC, the resultant colonies were
lifted off the plate using nitrocellulose membranes, and then the
membranes were placed on LB media containing kanamycin and
1 mM isopropyl-b-D-thiogalactopyranoside for 4 hours at 37uC to
induce transcription of insert DNA. Membranes were exposed to
chloroform-soaked blotting paper to lyse bacteria, blocked for 1 hr
using 5% milk in PBS with 0.25% Tween-20 (PBS/Tween),
washed five times in PBS/Tween, and then incubated overnight
with adsorbed sera at 1:10,000 dilution. After membranes were
washed 3 times with PBS/Tween, immunoreactive clones were
detected using anti-human IgG conjugated to horseradish
peroxidase (MP Biomedicals/Cappel, Aurora, OH) at a 1:20,000
dilution, and immunoblots were developed with an enhanced
chemiluminescence (ECL) kit (Amersham, Piscataway, NJ).
Reactive clones were recovered from the master plates and saved
as frozen glycerol stocks.
To confirm immunoreactive clones, secondary screening was
performed comparing IgG immunoreactivity of the clones against
E. coli BL21DE3 with an empty pET30c vector. Inserts of
confirmed clones were sequenced to identify gene insert.
Constructs designed to express the full length native protein were
generated by amplifying the entire ORF of identified genes by
PCR, and cloning these amplicons into pET30c as NdeI and NotI
inserts. Immunoreactivity of these full ORF clones was compared
to E. coli BL21DE3 with an empty pET30c vector. To assess
immunoreactivity of identified antigens among the pertinent
general population, immunoreactive clones were also screened
using pooled sera of individuals living in a typhoid endemic area
(Bangladesh). These sera were pre-adsorbed against in vitro grown
E. coli BL21DE3, as described above, to reduce background
reactivity against the host strain.
Functional classifications of identified proteins were assigned
using published articles and available protein information
resources, including J. Craig Venter Institute annotations
(http://cmr.jcvi.org/tigr-scripts/CMR/CmrHomePage.cgi) and
Pfam 26.0 (http://pfam.sanger.ac.uk/).
Purification of YncE
YncE (STY1479) was PCR-amplified from S. Typhi strain
CT18 and the product was cloned into Gateway vector
pDONR221 using BP reaction kit according to manufacturer’s
instructions (Invitrogen). The full length sequence was verified and
transferred from pDONR221 into the Gateway expression vector
pDEST17 using LR reaction kit (Invitrogen) generating
pDEST17His6-yncE. The reaction product was transformed first
into E. coli DH5a, and then the recovered plasmid was
transformed into the expression strain BL21AI. To overproduce
His6-YncE, E. coli BL21AI (pDEST17His6-yncE) was grown in
250 mL LB broth containing ampicillin at 37uC until OD600 0.6,
and then expression of his6-yncE was induced by the addition of
L(+) arabinose (0.2%). After 4 hours, the pellet was harvested by
centrifugation, and the cells were lysed by sonication after
resuspension in 15 mL lysis buffer (50 mM Tris Hcl, 5% glycerol,
0.1 M NaCl pH 8) containing 100 ug/ml lysozyme. Following
centrifugation, the pellet was washed in lysis buffer with and
without 1% Triton X-100, and the pellet was resuspended in
10 mL of 8 M urea, 50 mM NaH2PO4 and 300 mM NaCl
(pH 7.4). His6-YncE was purified by HisPur Cobalt Resin
(ThermoScientific, Rockford, Il) under denaturing conditions per
the manufacturer’s instructions. His6-YncE was then refolded by
dialysis into 25 mM Tris-HCL 0.15 M NaCl, pH 8.0 using
decreasing concentrations of urea. Product purity was assessed by
polyacrylamide gel electrophoresis and Coomassie staining, and
product identity was assessed by Mass spectrometry analysis.
Protein concentration was determined via Coomassie (Bradford)
Protein Assay Kit (ThermoScientific, Rockford, Il).
Evaluation of serum IgG and IgA responses to YncE and
S. Typhi capsular Vi antigen
To further characterize immunoreactivity of the antigen with
the most prominent immunoreactivity in our initial screening,
anti-YncE (STY1479) IgG and IgA responses were measured in
the sera of 10 S. Typhi carriers, 3 S. Paratyphi A carriers, 8
patients at acute (day 0–3) and convalescent phase (day 14–28) of
typhoid fever with confirmed S. Typhi bacteremia, 8 Nepalese
controls undergoing elective cholecystectomy with negative bile
cultures, and 8 healthy Bangladeshis, in duplicate. Plates were
coated with 100 ng/well of YncE and then sera were added at a
1:200 dilution. Bound antibody was detected with anti-human IgG
or IgA conjugated with horseradish peroxidase (Jackson Labora-
tories, Bar Harbor, ME) at a 1:1000 dilution, and peroxidase
activity was measured with the substrate 2,2-azinobis (ethyl-
benzthiazolinesulfonic acid). To compare across plates, kinetic
readings (mAb/sec) of samples were averaged, divided by kinetic
readings (mAb/sec) of an in-house pooled standard (pooled sera of
five S. Typhi carriers confirmed by biliary culture), and then
Typhoid Carrier IVIAT
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multiplied by 100. Results were expressed as units (U). The Mann-
Whitney U test was used to compare differences between groups.
For evaluation of anti-Vi IgG and IgA responses, ELISA plates
were coated with 200 ng/well of Vi antigen (Sanofi Pasteur, Lyon,
France). The above sera were applied at a 1:100 dilution, and
bound antibody was detected with anti-human IgG and IgA
conjugated with horseradish peroxidase at a 1:1000 dilution.
Peroxidase activity was measured with the substrate 2,2-azinobis
(ethylbenzthiazolinesulfonic acid). To compare anti-Vi responses
across plates, duplicate kinetic readings of samples were averaged,
divided by average kinetic readings of an in-house pooled
standard, and then multiplied by 100, as described above. Results
were expressed as units (U). Differences between groups were
assessed using the Mann-Whitney U test.
Results
S. Typhi antigens identified by IVIAT
In the primary screen of over 120,000 clones, 565 clones were
identified as immunogenic; 210 were confirmed by secondary
screening. Sequence analysis of these inserts (many of which
carried multiple potentially expressible ORFs) revealed 268 genes
of interest with over 20% of genes identified multiple times,
supporting validity of their identification and saturation of library
screening. We subsequently sub-cloned the full coding sequences
of 235 genes into individual expression plasmids, and identified 56
proteins with prominent IgG immunoreactivity using S. Typhi
carrier sera, comparing immunoreactivity of expression clones to a
clone containing an empty vector (Supplementary Table S1).
Forty-eight of the identified genes are encoded on the chromo-
some of S. Typhi, 5 are encoded on the drug resistance plasmid
pHCM1, and 3 on cryptic plasmid pHCM2. The most highly
represented functional groups included proteins of unknown
function and those involved in transport and binding, synthesis
or salvage of ribonucleotides, and energy metabolism.
To assess the degree of immunoreactivity of antigens identified
by IVIAT within the pertinent endemic-zone population, we
screened the 56 immunoreactive clones against pooled sera of
individuals living in a S. Typhi endemic area (Bangladeshi
residents of Dhaka) [26]. Of these 56 proteins, 13 proteins had
more prominent immunoreactivity when screened with sera of S.
Typhi carriers compared to sera of healthy Bangladeshis. These 13
proteins included a number of putative membrane proteins,
lipoproteins, and hemolysin-related proteins (Table 1). YncE, a
possible ATP- binding protein, had the overall highest differential
immunoreactivity compared to healthy endemic-zone control sera
in our immunoblot assay.
Anti-YncE serum responses as a diagnostic biomarker for
asymptomatic S. Typhi carriage
To further characterize whether the immunoreactivity to YncE
in S. Typhi carriers was specific, we also evaluated the
immunoreactivity to YncE using sera of 5 groups of individuals:
(1) S. Typhi carriers, (2) patients at the acute and convalescent
phase of typhoid fever, (3) S. Paratyphi A carriers, (4) individuals
who underwent cholecystectomy in Nepal whose bile cultures were
negative for any pathogen, and (5) healthy controls from a typhoid
endemic area (Dhaka, Bangladesh). We found significantly higher
IgG immunoreactivity to YncE in S. Typhi carriers compared to
bile culture-negative patients (p = 0.0205), healthy Bangladeshis
(p = 0.0005), and patients at the acute and convalescent phases of
typhoid infection (p= 0.0044 and p= 0.0266, respectively); there
was a trend toward statistical significance when compared to S.
Paratyphi A carriers (p = 0.21) (Figure 1A). Of the 10 S. Typhi
carriers, 7 (70%) had an anti-YncE IgG response (Units .100).
None of 8 bile culture negative controls (0%), 0 of 8 healthy
Bangladeshis (0%), 0 of 3 S. Paratyphi A carriers (0%) and 1 of 8
(12.5%) Bangladeshis at the acute and convalescent phase of S.
Typhi had an anti-YncE IgG response. Thus, in our small subset
of patients, using a cut-off value of .100 Units (U), anti-YncE IgG
had a sensitivity of 70%, and specificity of 100% when using
endemic zone healthy individuals and cholecystectomy patients
without detectable S. Typhi as controls. The specificity decreased
to 95% if we included patients with acute typhoid fever.
Although, the values did not reach statistical significance, S.
Typhi carriers also had a higher IgA immunoreactivity to YncE
compared to our two control groups: bile culture-negative patients
(p = 0.2370) and healthy Bangladeshis (p = 0.2031) (Figure 1B).
There was no significant difference between the IgA immunore-
activity to YncE in S. Typhi carriers in comparison to patients
Table 1. Proteins identified by IVIAT with higher IgG immunoreactivity in S. Typhi carriers compared to healthy typhoid-endemic
zone controls.
Locus Gene Function
STY0712 corC Hemolysin-related protein
STY1364 Hypothetical periplasmic protein
STY1479 yncE Possible ATP-binding protein
STY2155 sirA Invasion response-regulator
STY2248 pduG PduG protein
STY2386 Putative lipoprotein
STY2454 yejE Putative binding-protein-dependent transporter
STY2657 xapB Xanthosine permease
STY3709 purH Phosphoribosylaminoimidazolecarboxamideformyltransferase and IMP cyclohydrolase (bifunctional enzyme)
HCM1.137 repE Replication initiation protein
HCM1.213c Putative transposase
HCM2.0043 Hypothetical protein
HCM2.0069c Hypothetical protein
doi:10.1371/journal.pntd.0002335.t001
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convalescing from acute typhoid infection or S. Paratyphi A
carriers.
Comparison with anti-Vi serum responses
Since immune responses to S. Typhi Vi antigen have been the
best characterized diagnostic method for identifying S. Typhi
carriers to date, we also assessed the anti-Vi IgG and IgA
responses in the same cohort of patients. We found significantly
higher IgG immunoreactivity to Vi antigen in S. Typhi carriers
compared to PTA carriers (p = 0.0070), bile culture negative
controls (p = 0.0343), healthy Bangladeshis (p = 0.0021), and
patients at the acute phase of typhoid infection (p = 0.0155).
(Figure 2A). There was a trend toward statistical significance when
the immunoreactivity of S. Typhi carriers to Vi antigen was
compared to patients at the convalescent phase of typhoid
infection (p = 0.0830) (Figure 2A). In our evaluation of IgA anti-
Vi responses, we did find a significant difference in the
immunoreactivity of S. Typhi carriers compared to healthy
Bangladeshis (p = 0.0155), and patients convalescing from acute
typhoid infection (p= 0.0266) (Figure 2B). There was no significant
difference in immune responses between S. Typhi carriers and
bile-culture negative patients, S. Paratyphi A carriers, or patients
at the acute phase of typhoid infection. The sensitivity for anti-Vi
IgG and IgA was 40% (cutoff value .1250 U) and 50% (cutoff
value .1250 U), respectively. The specificity was 100% for IgG
irrespective of controls. For IgA, the specificity was 97% when
using endemic zone healthy individuals and cholecystectomy
patients without detectable S. Typhi as controls. The specificity
was 94% if patients with acute typhoid fever were included in the
analysis.
Figure 1. Characterization of anti- YncE immune responses. Anti-YncE IgG (A) and IgA (B) responses in S. Typhi carriers (Typhi carrier), S.
Paratyphi A carriers (PTA carrier), Nepalese controls undergoing elective cholecystectomy with negative bile cultures (GB control), Healthy
Bangladeshi controls (HB control), and patients at the day 0–3 acute (Typhi acute) and day 14–28 convalescent phase (Typhi conv) of typhoid fever
with confirmed S. Typhi bacteremia.
doi:10.1371/journal.pntd.0002335.g001
Figure 2. Characterization of anti- Vi immune responses. Anti- Vi antigen IgG (A) and IgA (B) responses were evaluated in S. Typhi carriers
(Typhi carrier), S. Paratyphi A carriers (PTA carrier), Nepalese controls undergoing elective cholecystectomy with negative bile cultures (GB control),
healthy Bangladeshi controls (HB control), and patients at the day 0–3 acute (Typhi acute) and day 14–28 convalescent phase (Typhi conv) of typhoid
fever with confirmed S. Typhi bacteremia.
doi:10.1371/journal.pntd.0002335.g002
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Combined YncE and Vi antibody measurements for the
detection of S. Typhi carriers
In our analysis, using a cut-off value of .100 U of anti-YncE
IgG and/or .1250 U anti-Vi IgA, we could identify 8 out of 10 S.
Typhi carriers. There was no added benefit seen when pairing
anti-YncE responses with anti-Vi IgG.
Discussion
In our immunoscreen using IVIAT, we were able to identify 56
immunogenic S. Typhi proteins using the sera of S. Typhi carriers.
Of these, 13 had higher immunoreactivity when screened with S.
Typhi carrier sera compared to sera of endemic zone residents.
These proteins represent a working list of candidate diagnostic
biomarkers of asymptomatic S. Typhi carriage and their analysis
may further our understanding of survival adaptations of S. Typhi
in chronic carriers.
Human epidemiologic studies as well as murine models of S.
Typhi carriage suggest that gallstones facilitate the development of
the chronic carrier state [5]. In support of this, we identified SirA
in our IVIAT screen, which is part of the two-component response
regulator SirA-BarA [27]. In S. Typhimurium, this regulator plays
a role in the down-regulation of genes involved in invasion (i.e.
Salmonella Pathogenicity Island-1) when the bacterium is in the
presence of bile [28], and mutations in sirA result in decreased
biofilm formation on plastic surfaces [28]. The role SirA may play
in human or murine Salmonella carriage, or why a cytoplasmic
regulatory protein generated a humoral response, has yet to be
characterized. Other proteins identified in the IVIAT screen may
also affect carriage in the presence of gallstones.
Although S. Typhi may persist in the gallbladder in association
with gallstones [3], S. Typhi likely has other niches of infection,
including the gallbladder epithelium, biliary tree, and in macro-
phages of mesenteric lymph nodes [2,3,5,16–18]. Proteins
identified in our screen may play a role in persistence of S. Typhi
within host cells or the stringent environment of bile. For instance,
YejE is a putative permease that is thought to be a component of a
putative ABC transporter system. YejE plays a role in survival
within epithelial cells and in antimicrobial peptide resistance [29].
In both S. Typhi and S. Typhimurium, yejE expression is
upregulated inside host macrophages [30,31]. PduG is a protein
encoded within the pdu operon that is part of the coenzyme B12-
dependent 1,2-propranediol utilization pathway [32]. This operon
is upregulated during acute S. Typhi and S. Paratyphi A infection
in humans [24,33], and may be associated with use of alternative
carbon sources in the nutrient-limited environment of the
Salmonella-containing vacuole within host cells [32]. We also
identified PurH and XapB, which are proteins involved in purine
biosynthesis and acquisition, respectively, by functional classifica-
tion. In S. Typhimurium, PurH is associated with virulence [34],
and we have previously shown that genes involved in purine
synthesis are upregulated during acute typhoid infection in
humans [24]. CorC is a hemolysin-related protein involved in
magnesium and cobalt efflux, and is part of the CorA transporter
system containing CorA-D [35]. CorA, with associated proteins, is
required for efflux of Mg2+ [35]. CorA is required for S.
Typhimurium virulence [36], and corA is expressed by S. Typhi
during acute human infection [24]. However, while some
information is known regarding the above mentioned Salmonella
carrier-specific antigens, their potential role in carriage is presently
unclear.
The majority of the genes identified by IVIAT encode for
proteins with putative or unknown function. For example,
STY2386 is an uncharacterized lipoprotein found uniquely in
Salmonella. STY1364 is a hypothetical periplasmic protein in S.
Typhi and S. Paratyphi A, and is rarely found in other Salmonella
spp. STY1364 belongs to the structural classification of bacterial
enterotoxins and is a subtilase cytotoxin subunit B-like protein. We
previously identified STY1364 in S. Typhi infected patients using
a separate immunoscreening technology (immunoaffinity proteo-
mic-based technology, IPT) [23].
In our screening, YncE (STY1479) was the most immunoreactive
antigen identified, and we thus focused our more detailed analysis of
immunoreactivity on this antigen. YncE has a putative N-terminal
signal sequence suggestive of export, with ATP and DNA-binding
domains. yncE is present in a number of Salmonella spp., and has
orthologs in a number of other Gram-negative enteric organisms,
including Escherichia coli, Citrobacter spp, and Shigella spp. In E. coli,
YncE is secreted into the periplasm via the Sec-dependent pathway
[37], and its expression is induced under iron-restricted conditions
when repression by the Fur protein is relieved [38]. Its role in the
pathogenesis of Salmonella infection has yet to be characterized.
However, our results suggest that it may be involved in long-term
persistence of the bacterium in chronic carriers.
In our analysis, we show that S. Typhi carriers have an IgG
response to YncE that is not present in bile culture-negative
controls in Nepal or healthy controls in Bangladesh. Although we
did not reach statistical significance in this small pilot study, a
similar trend was seen for IgA as well. One patient convalescing
from acute typhoid infection had a detectable IgG anti-YncE
response, and another had an IgA response. This may suggest that
anti-YncE responses occur during acute disease; however, it
should be noted that we do not know the current or future carrier
status of the acute typhoid patients, and an elevated level of YncE
during an episode of typhoid fever may represent an acute on
chronic infection, or may be a marker of future progression to the
chronic carrier state.
All of the identified genes except three (xapB and the two genes
encoded on the cryptic plasmid pHCM2) are present in the
genome of S. Paratyphi A sequenced strains ATCC 9150 and
AKU 12601 based on ,60% nucleotide identity. It is interesting
then, that we did not see an IgG or IgA immune response to YncE
in S. Paratyphi A carriers. This finding may suggest that S. Typhi
and S. Paratyphi A use different strategies to persist in chronic
carriers, that expression of YncE may be distinct in these two
organisms, or that our study did not have sufficient power to
examine this, as it included only three S. Paratyphi A carriers.
Despite this, in our small cohort of patients, measurement of
anti-YncE IgG responses did appear to be both relatively sensitive
and specific for identifying asymptomatic chronic S. Typhi
carriers. Further studies will be needed to evaluate the diagnostic
capabilities of anti-YncE responses in a larger and different cohort
of patients. Of note, if such studies demonstrate higher anti-YncE
IgA levels in S. Typhi carriers than in control groups, that
information could support consideration of a salivary diagnostic to
facilitate community-based screening for carriage.
The other antigens identified in our IVIAT analysis may also be
useful diagnostic biomarkers of S. Typhi carriage, and the
sensitivity of carrier detection may be improved when responses
against these or anti-Vi responses are paired with responses to
YncE. For example, in our analysis, using a cut-off value of
.100 U of anti YncE IgG and/or .1250 U anti-Vi IgA, we
could identify 8 out 10 S. Typhi carriers. There was no added
benefit seen when pairing anti-YncE responses with anti-Vi IgG.
Another potential pairing could include a marker of biliary tract
inflammation such as elevated bilirubin values, since S. Typhi
carriage is often associated with chronic inflammation of the
gallbladder [5]. We did not assess this parameter in this study.
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Our study has a number of limitations. First, the number of
patients involved in our study is small, although it should be noted
that our analysis is the largest study involving immunoproteomic
screening and pilot confirmation of the carriage state that includes
appropriate control groups. A second limitation is that IVIAT
identifies proteins that are uniquely expressed in vivo compared to
standard in vitro culturing, and that also induce an antibody
response. Proteins that induce cellular responses and/or that are
expressed both in vivo and in vitro may also play a role in the
pathogenesis of chronic carriage and serve as useful biomarkers for
asymptomatic carriage. In addition, altering in vitro culturing
conditions may also change the expression profile of S. Typhi,
thereby changing the comparison groups. In addition, IVIAT does
not identify non-protein antigens that may also be useful in
diagnostic assays. However, despite these limitations, we have used
IVIAT to identify a subset of immunoreactive antigens in S. Typhi
carriers, including YncE. Further evaluation of YncE and other
identified antigens could lead to the development of improved
diagnostic assays to detect asymptomatic S. Typhi carriers in
typhoid endemic zones, and analysis of YncE, along with other
identified antigens, could lead to an improved understanding of
host-pathogen interactions during chronic carriage of S. Typhi in
humans.
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